What is GWs position on crude herbal cannabis?
GW has never endorsed or supported the idea of distributing or legalizing crude herbal cannabis for medical use. In both our publications and presentations, we have consistently maintained that only a cannabinoid medication–one that is standardized in composition, formulation, and dose, administered by means of an appropriate delivery system, and tested in properly controlled preclinical and clinical studies–can meet the standards of regulatory authorities around the world, including those of the FDA. These criteria are also mandatory if the modern medical model—informed patients working with, and being advised by, knowledgeable physicians to identify appropriate treatment options–is ever to be attained with a cannabinoid medication. We have also repeatedly stressed that these regulatory processes provide important protections for patients, and we believe that any cannabinoid medication must be subjected to, and satisfy, such rigorous scrutiny.
